The recombinant anti-tick vaccine Gavac®, produced since 1996 in the Center of Genetic Engineering and Biotechnology (CIGB, Spanish acronym) in Camagüey, has experienced over the last three years a steady increase in its demand in Cuba.

The Integrated Control Program of Ticks (ICPT) in Cuba is an example of how the application of modern biotechnologies, in this case Gavac®, vaccine destined to control the tick Rhipicephalus (Boophilus) microplus in beef cattle, can have a real impact in the country’s economic life. Or so was said at the VII National Workshop of Strategic Agricultural Products, that concluded today in Camagüey.

The evaluation of the impact of Gavac®in Cuba, the analysis of the results of the first vaccination campaign in 2019 and the presentation of strategies to accomplish the incorporation of 2 million cows to the Integrated Control Program of Ticks (ICPT), are the main themes to be debated during the National Workshop of Strategic Agricultural Products, that is developing in the province from today to the next 15^th.

The recombinant vaccine against ticks Gavac, produced in the Center of Genetic Engineering and Biotechnology (CIGB), of this city, continues its application in the Cuban cattle mass, in the determination to resist the harmful effects that this arachnid causes.